| sodium deoxycholate / Generic mfg. |
'O' study, ACTRN12607000626460: A Phase 2 Study of ATX 101 (Sodium Deoxycholate for injection) Given by Three Dosing Paradigms for the Reduction of Submental Fat (Double Chin). |
|
|
| Not yet recruiting | 2 | 60 | | | Kythera Biopharmaceuticals Inc, Kythera Biopharmaceuticals Inc | Submental Fat | | | | |
NCT00608842: Phase 2 Study for the Treatment of Superficial Lipomas |
|
|
| Completed | 2 | 62 | US | Deoxycholic Acid Injection, sodium deoxycholate, ATX-101, Placebo | Kythera Biopharmaceuticals | Lipoma | 08/08 | 01/10 | | |
| Completed | 2 | 73 | Canada, Europe, RoW | Deoxycholic Acid Injection, ATX-101, Placebo | Kythera Biopharmaceuticals | Moderate or Severe Submental Fullness | 12/08 | 12/08 | | |
NCT01032889: Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study |
|
|
| Completed | 2 | 129 | US | Deoxycholic acid injection, ATX-101, Kybella, Placebo | Kythera Biopharmaceuticals | Moderate or Severe Submental Fullness | 12/10 | 12/10 | | |
|
NCT02159729: Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 |
|
|
| Completed | 2 | 205 | Europe, Canada, US, RoW | Placebo, ATX-101 (1 mg/cm^2), ATX-101 (2 mg/cm^2), ATX-101 (4 mg/cm^2) | Kythera Biopharmaceuticals | Submental Fat, Healthy | 12/15 | 12/15 | | |
| Not yet recruiting | 1/2 | 72 | | | Kythera Biopharmaceuticals Inc, Kythera Biopharmaceuticals Inc | Unwanted subcutaneous fat in the submental area | | | | |
| Completed | 1/2 | 85 | Canada, Europe, RoW | Deoxycholic Acid Injection, ATX-101, Placebo | Kythera Biopharmaceuticals | Moderate or Severe Submental Fullness | 10/08 | 10/08 | | |
